CRCA · ProShares Ultra CRCL
United States · RS rating 26 · As of 2026-10-14
| Price | 16.11 USD |
|---|---|
| 1-day change | -10.7% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 13 / 95 / 4 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 11 / 4 |
| Industry group (rank) | Finance-ETF / ETN (48) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +89.8% |
| Market cap (USD) | – |